EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Cendakimab in Adults and Adolescents with Eosinophilic Esophagitis

Evan S Dellon, Christina M Charriez, Sandra Zhang, Gary W Falk, Salvatore Oliva, Christopher Ma, Jesse Siffledeen, Shauna Schroeder, Hamish Philpott, Tim Vanuytsel, Yasuhiko Abe, Kexuan Li und 5 weitere

NEJM Evidence · 23.09.2025 · 4 (10)

DOI: 10.1056/evidoa2500095 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift NEJM Evidence, erschienen am 23.09.2025. Verfasst von Evan S Dellon und 16 weiteren Autor:innen. Beteiligte Einrichtung: Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel H…. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Eosinophilic EsophagitisAntibodies, Monoclonal, HumanizedHumansMaleAdultFemaleAdolescentMiddle AgedAgedYoung AdultChildDouble-Blind MethodTreatment OutcomeDeglutition Disorders

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill.
  • Bristol Myers Squibb, Princeton, NJ.
  • Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
  • Pediatric Gastroenterology and Liver Unit, Maternal and Child Health Department, Sapienza University of Rome, University Hospital Umberto I, Rome, Italy.
  • Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada.
  • Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton.

Zitieren

APA

Dellon, E. S., Charriez, C. M., Zhang, S., Falk, G. W., Oliva, S., Ma, C., Siffledeen, J., Schroeder, S., Philpott, H., Vanuytsel, T., Abe, Y., Li, K., Zema, C. L., Venkatasamy, A., Yeshokumar, A. K., Oh, Y. S., & Schoepfer, A. (2025). Cendakimab in Adults and Adolescents with Eosinophilic Esophagitis. NEJM Evidence, 4(10). https://doi.org/10.1056/evidoa2500095

Vancouver

Dellon ES, Charriez CM, Zhang S, Falk GW, Oliva S, Ma C, et al. Cendakimab in Adults and Adolescents with Eosinophilic Esophagitis. NEJM Evidence. 2025;4(10). doi:10.1056/evidoa2500095

BibTeX
@article{Dellon2025,
  author = {Dellon, Evan S and Charriez, Christina M and Zhang, Sandra and Falk, Gary W and Oliva, Salvatore and Ma, Christopher and Siffledeen, Jesse and Schroeder, Shauna and Philpott, Hamish and Vanuytsel, Tim and Abe, Yasuhiko and Li, Kexuan and Zema, Carla L and Venkatasamy, Ashwini and Yeshokumar, Anusha K and Oh, Young S and Schoepfer, Alain},
  title = {Cendakimab in Adults and Adolescents with Eosinophilic Esophagitis},
  journal = {NEJM Evidence},
  year = {2025},
  volume = {4},
  number = {10},
  doi = {10.1056/evidoa2500095}
}
Kostenlos starten →